Your browser doesn't support javascript.
loading
Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia.
Maiques-Diaz, Alba; Spencer, Gary J; Lynch, James T; Ciceri, Filippo; Williams, Emma L; Amaral, Fabio M R; Wiseman, Daniel H; Harris, William J; Li, Yaoyong; Sahoo, Sudhakar; Hitchin, James R; Mould, Daniel P; Fairweather, Emma E; Waszkowycz, Bohdan; Jordan, Allan M; Smith, Duncan L; Somervaille, Tim C P.
Afiliação
  • Maiques-Diaz A; Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre Building, 555 Wilmslow Road, Manchester M20 4GJ, UK.
  • Spencer GJ; Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre Building, 555 Wilmslow Road, Manchester M20 4GJ, UK.
  • Lynch JT; Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre Building, 555 Wilmslow Road, Manchester M20 4GJ, UK.
  • Ciceri F; Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre Building, 555 Wilmslow Road, Manchester M20 4GJ, UK.
  • Williams EL; Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre Building, 555 Wilmslow Road, Manchester M20 4GJ, UK.
  • Amaral FMR; Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre Building, 555 Wilmslow Road, Manchester M20 4GJ, UK.
  • Wiseman DH; Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre Building, 555 Wilmslow Road, Manchester M20 4GJ, UK.
  • Harris WJ; Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre Building, 555 Wilmslow Road, Manchester M20 4GJ, UK.
  • Li Y; Computational Biology Support, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre Building, 555 Wilmslow Road, Manchester M20 4GJ, UK.
  • Sahoo S; Computational Biology Support, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre Building, 555 Wilmslow Road, Manchester M20 4GJ, UK.
  • Hitchin JR; Drug Discovery Unit, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre Building, 555 Wilmslow Road, Manchester M20 4GJ, UK.
  • Mould DP; Drug Discovery Unit, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre Building, 555 Wilmslow Road, Manchester M20 4GJ, UK.
  • Fairweather EE; Drug Discovery Unit, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre Building, 555 Wilmslow Road, Manchester M20 4GJ, UK.
  • Waszkowycz B; Drug Discovery Unit, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre Building, 555 Wilmslow Road, Manchester M20 4GJ, UK.
  • Jordan AM; Drug Discovery Unit, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre Building, 555 Wilmslow Road, Manchester M20 4GJ, UK.
  • Smith DL; Biological Mass Spectrometry Facility, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre Building, 555 Wilmslow Road, Manchester M20 4GJ, UK.
  • Somervaille TCP; Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre Building, 555 Wilmslow Road, Manchester M20 4GJ, UK. Electronic address: tim.somervaille@cruk.manchester.ac.uk.
Cell Rep ; 22(13): 3641-3659, 2018 03 27.
Article em En | MEDLINE | ID: mdl-29590629
ABSTRACT
Pharmacologic inhibition of LSD1 promotes blast cell differentiation in acute myeloid leukemia (AML) with MLL translocations. The assumption has been that differentiation is induced through blockade of LSD1's histone demethylase activity. However, we observed that rapid, extensive, drug-induced changes in transcription occurred without genome-wide accumulation of the histone modifications targeted for demethylation by LSD1 at sites of LSD1 binding and that a demethylase-defective mutant rescued LSD1 knockdown AML cells as efficiently as wild-type protein. Rather, LSD1 inhibitors disrupt the interaction of LSD1 and RCOR1 with the SNAG-domain transcription repressor GFI1, which is bound to a discrete set of enhancers located close to transcription factor genes that regulate myeloid differentiation. Physical separation of LSD1/RCOR1 from GFI1 is required for drug-induced differentiation. The consequent inactivation of GFI1 leads to increased enhancer histone acetylation within hours, which directly correlates with the upregulation of nearby subordinate genes.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fatores de Transcrição / Leucemia Mieloide Aguda / Proteínas de Ligação a DNA / Histona Desmetilases Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fatores de Transcrição / Leucemia Mieloide Aguda / Proteínas de Ligação a DNA / Histona Desmetilases Idioma: En Ano de publicação: 2018 Tipo de documento: Article